Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) have received an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $16.00.

CNAT has been the subject of a number of analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Seaport Global Securities reissued a “buy” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective (down previously from $18.00) on shares of Conatus Pharmaceuticals in a report on Thursday, November 2nd.

A number of hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its stake in Conatus Pharmaceuticals by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock worth $464,000 after buying an additional 1,655 shares during the period. FNY Partners Fund LP boosted its stake in Conatus Pharmaceuticals by 98.0% during the second quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after buying an additional 9,800 shares during the period. New York State Common Retirement Fund boosted its stake in Conatus Pharmaceuticals by 156.4% during the third quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after buying an additional 14,700 shares during the period. Voya Investment Management LLC purchased a new position in Conatus Pharmaceuticals during the second quarter worth about $101,000. Finally, Wells Fargo & Company MN boosted its stake in Conatus Pharmaceuticals by 3,098.0% during the third quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after buying an additional 18,588 shares during the period. 34.06% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Conatus Pharmaceuticals Inc. (CNAT) Given Consensus Rating of “Buy” by Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/20/conatus-pharmaceuticals-inc-cnat-given-consensus-rating-of-buy-by-brokerages.html.

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at $4.22 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69. Conatus Pharmaceuticals has a 1-year low of $1.73 and a 1-year high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative net margin of 80.98% and a negative return on equity of 83.02%. The firm had revenue of $9.57 million during the quarter, compared to analysts’ expectations of $16.06 million. During the same period in the prior year, the company posted ($0.31) EPS. research analysts forecast that Conatus Pharmaceuticals will post -0.65 EPS for the current fiscal year.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.